Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 0.84 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.84 |
| ▸ | RELA | Q04206 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rocaglamide SCHEMBL29439568 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL10054686 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL752144 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL751061 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL29407815 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL24127774 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL20386162 | 0.91 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL12182311 | 0.84 | EIF4A1 (0.87) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocagloic Acid SCHEMBL750035 | 0.82 | EIF4A1 (0.86) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL15079078 | 0.82 | EIF4A1 (0.86) | EIF4A1NFKB1RELACYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | Cartesian Therapeutics Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CARTESIAN THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4568750-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | Cartesian Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12324826-B2 | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates | JOMOCO, CORP. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250177360-A1 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE | CARTESIAN THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-3858348-B1 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS | CARTESIAN THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024229432-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229350-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS FOR DIABETES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229380-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS IN AUTOIMMUNE LIVER DISEASES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229370-A1 | COMPOSITIONS AND METHODS FOR TREATING GVHD | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2022217095-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220323607-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022150335-A1 | VIRAL VECTOR DOSING PROTOCOLS | SELECTA BIOSCIENCES, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022098901-A1 | COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | SELECTA BIOSCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133864-A1 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | SELECTA BIOSCIENCES INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11298342-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity | SELECTA BIOSCIENCES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3976802-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | Selecta Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220071968-A1 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3962537-A1 | METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS | Selecta Biosciences, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11235057-B2 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses | SELECTA BIOSCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133864-A1 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | FCGR3B, SERPINB1, SERPINA6 | EIF4A1 3388/4885NFKB1 1914/4885RELA 2329/4885 |
| US-20250177360-A1 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE | SERPINA6, FCGRT, FCGR3B | EIF4A1 2176/4885NFKB1 2236/4885RELA 3688/4885 |
| US-11235057-B2 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses | CD47, LY96, CD74 | EIF4A1 1468/4885NFKB1 1225/4885RELA 1562/4885 |
| US-11298342-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity | CD74, HLA-DRB1, MSR1 | EIF4A1 1559/4885NFKB1 2334/4885RELA 3412/4885 |
| US-20220071968-A1 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | IL2, CD74, HLA-DRB1 | EIF4A1 1244/4885NFKB1 1750/4885RELA 3289/4885 |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | HLA-C, CPA3, HLA-A | EIF4A1 1637/4885NFKB1 2106/4885RELA 3774/4885 |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CD74, CCR1, MSR1 | EIF4A1 1020/4885NFKB1 1984/4885RELA 3618/4885 |
| US-20220323607-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | IL2, IL2RA, ICOS | EIF4A1 2113/4885NFKB1 1553/4885RELA 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.